Financials SynAct Pharma AB

Stocks

Real-time Estimate Cboe Europe 06:25:49 2026-10-22 EDT			5-day change	1st Jan Change
17.18 ^SEK	-1.49%		+0.83%	-24.34%

09-16	Synact Pharma's resomelagon highlighted by WHO for dengue fever	FW
09-16	SynAct Pharma Identifies Resomelagon As One Of Six Dengue Drug Candidates With Evidence Supporting Further Clinical Development	CI

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net sales ¹	-	-	-	-	-	44.25	21.6	77.9
Change	-	-	-	-	-	-	-51.19%	260.65%
EBITDA ¹	-	-	-224.5	-89.98	-116.5	-47.49	-33.16	28.5
Change	-	-	-	59.92%	-29.52%	59.25%	30.17%	185.95%
EBIT ¹	-	-	-224.5	-89.98	-116.5	-47.75	-33.29	28.5
Change	-	-	-	59.92%	-29.52%	59.03%	30.28%	185.61%
Interest Paid ¹	-	-	-	-	-2.451	-6.84	-2.92	-
Earnings before Tax (EBT) ¹	-	-	-224.3	-90.82	-119	-51.15	-34.75	28.5
Change	-	-	-	59.5%	-31.01%	57.01%	32.06%	182.01%
Net income ¹	-69.3	-99.2	-215.8	-82.4	-110.8	-47.08	-31.92	28.5
Change	-	-43.14%	-117.54%	61.82%	-34.5%	57.51%	32.21%	189.29%
Announcement Date	2/11/22	2/17/23	2/23/24	2/18/25	2/18/26	-	-	-

¹SEK in Million

Estimates

Fiscal Period: December	2021 Q4	2023 Q2	2023 Q3	2023 Q4	2025 Q1	2025 Q2	2025 Q3
Net sales ¹	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-
EBITDA	-	-	-	-91.06	-28.1	-	-
Change	-	-	-	-	69.14%	-	-
EBIT	-	-	-31.69	-91.06	-28.1	-	-
Change	-	-	-	-187.33%	69.14%	-	-
Charge d'intérêts	-	-	-	-	-	-	-
Earnings before Tax (EBT)	-	-	-31.99	-90.54	-30.33	-	-
Change	-	-	-	-183.05%	66.51%	-	-
Net income	-26.21	-43.51	-31.88	-90.54	-24.68	-	-
Change	-	-66.01%	26.74%	-184.03%	72.74%	-	-
Announcement Date	2/11/22	8/4/23	10/24/23	2/23/24	5/27/25	8/18/25	10/30/25

¹SEK in Million

Estimates

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net Debt ¹	-	-	-	-46.8	-53.4	24.8	74.2	-
Change	-	-	-	-	-14.1%	146.44%	199.19%	-
Announcement Date	2/11/22	2/17/23	2/23/24	2/18/25	2/18/26	-	-	-

¹SEK in Million

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025
CAPEX ¹	-	-	-	-	-	-
Change	-	-	-	-	-	-
Free Cash Flow (FCF) ¹	-12.13	-43.37	-84.11	25.55	-62.5	-62.83
Change	-	-257.55%	-93.95%	130.38%	-344.61%	-0.54%
Announcement Date	4/19/21	4/29/22	4/13/23	3/26/24	4/10/25	4/15/26

¹SEK in Million

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027	2028
Profitability
EBITDA Margin (%)	-	-	-	-	-	-	-107.32%	-153.52%	36.59%
EBIT Margin (%)	-	-	-	-	-	-	-107.91%	-154.12%	36.59%
EBT Margin (%)	-	-	-	-	-	-	-115.59%	-160.88%	36.59%
Net margin (%)	-	-	-	-	-	-	-106.41%	-147.78%	36.59%
FCF margin (%)	-	-	-	-	-	-	-	-	-
FCF / Net Income (%)	-	-	-	46.42%	108.25%	-	-	-	-
Profitability
ROA	-82.32%	-159.89%	-70.16%	-46.86%	-22.48%	-29.6%	-	-	-
ROE	-189.27%	-377.3%	-134.62%	-142.59%	-42.22%	-57.65%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-0.52x	-2.24x	-
Debt / Free cash flow	-	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	-	-	-	-	-	-	-	-
CAPEX / EBITDA (%)	-	-	-	-	-	-	-	-	-
CAPEX / FCF (%)	-	-	-	-	-	-	-	-	-
Items per share
Cash flow per share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
EPS ¹	-	-2.68	-3.6	-6.64	-2.08	-2.17	-1.68	-0.98	-
Change	-	-	-34.33%	-84.44%	68.67%	-4.33%	22.58%	41.67%	-
Nbr of stocks (in thousands)	-	26,006	29,648	35,571	46,487	53,330	55,998	55,998	-
Announcement Date	-	2/11/22	2/17/23	2/23/24	2/18/25	2/18/26	-	-	-